HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

K. Theys; J. Vercauteren; J. Snoeck; M. Zazzi; R. J. Camacho; C. Torti; E. Schülter; B. Clotet; A. Sönnerborg; A. De Luca; Z. Grossman; D. Struck; A. M. Vandamme; A. B. Abecasise

Journal ArticleOPEN ACCESS

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Antimicrobial Agents and Chemotherapy (2013) 57(2) 1053-1056

DOI: 10.1128/AAC.01668-12

36Citations

42Readers

Abstract

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways. Copyright © 2013, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Theys, K., Vercauteren, J., Snoeck, J., Zazzi, M., Camacho, R. J., Torti, C., … Abecasise, A. B. (2013). HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrobial Agents and Chemotherapy, 57(2), 1053–1056. https://doi.org/10.1128/AAC.01668-12

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Abstract

Cite

Register to see more suggestions